🧪
hypothesis

Vesicle Size-Selective Nanobody Penetration

Hypothesis

Vesicle Size-Selective Nanobody Penetration

Nanobodies designed with size-selective membrane penetration mechanisms could preferentially enter enlarged tau-containing vesicles while having reduced penetration into normal-sized cellular vesicles.
🧬 MAPT🩺 molecular-biology🎯 Composite 46%💱 $0.52▲6.0%active
molecular biology
EvidencePending (0%)📖 5 cit🗣 1 debates 5 support 1 oppose
✓ All Quality Gates Passed
Mechanistic 0.50 (15%) Evidence 0.50 (15%) Novelty 0.50 (12%) Feasibility 0.50 (12%) Impact 0.00 (12%) Druggability 0.50 (10%) Safety 0.50 (8%) Competition 0.50 (6%) Data Avail. 0.50 (5%) Reproducible 0.50 (5%) KG Connect 0.24 (8%) 0.455 composite
☰ Compare⚔️ Duel⚛️ Collide
📄 Export LaTeX
arXiv PreprintNeurIPSNature MethodsPLOS ONE
📖 Export BibTeXinteract with this hypothesis
Composite46%

🧪 Overview

Nanobodies designed with size-selective membrane penetration mechanisms could preferentially enter enlarged tau-containing vesicles while having reduced penetration into normal-sized cellular vesicles.

🧬 Mechanism

🔗 Mechanism from KG for MAPT

Auto-built from this analysis's top knowledge-graph edges.

graph TD
    phosphatidylserine_exposu["phosphatidylserine exposure"] -->|associated with| APOPTOSIS["APOPTOSIS"]
    pH_sensitive_membrane_fus["pH-sensitive_membrane_fusion_domain"] -->|activates| acidic_microenvironment["acidic_microenvironment"]
    phosphatidylserine_bindin["phosphatidylserine-binding_domain"] -->|binds| phosphatidylserine["phosphatidylserine"]
    curvature_sensitive_cell_["curvature-sensitive_cell_penetrating_peptide"] -->|penetrates| curved_membranes["curved_membranes"]
    ATP_depleted_environment["ATP-depleted_environment"] -->|enables| membrane_penetration["membrane_penetration"]
    tau_protein["tau_protein"] -->|interacts with| phosphatidylserine_1["phosphatidylserine"]
    tau_protein_2["tau_protein"] -->|induces| membrane_curvature["membrane_curvature"]
    tau_aggregation["tau_aggregation"] -->|causes| pH_acidification["pH_acidification"]
    tau_aggregation_3["tau_aggregation"] -->|disrupts| cholesterol_depletion["cholesterol_depletion"]
    tau_conformational_change["tau_conformational_change"] -->|triggers| membrane_disruption["membrane_disruption"]
    tau_aggregation_4["tau_aggregation"] -->|causes| ATP_depletion["ATP_depletion"]
    tau_aggregation_5["tau_aggregation"] -->|disrupts| membrane_asymmetry["membrane_asymmetry"]
    style phosphatidylserine_exposu fill:#4fc3f7,stroke:#333,color:#000
    style APOPTOSIS fill:#ce93d8,stroke:#333,color:#000
    style pH_sensitive_membrane_fus fill:#4fc3f7,stroke:#333,color:#000
    style acidic_microenvironment fill:#4fc3f7,stroke:#333,color:#000
    style phosphatidylserine_bindin fill:#4fc3f7,stroke:#333,color:#000
    style phosphatidylserine fill:#4fc3f7,stroke:#333,color:#000
    style curvature_sensitive_cell_ fill:#4fc3f7,stroke:#333,color:#000
    style curved_membranes fill:#4fc3f7,stroke:#333,color:#000
    style ATP_depleted_environment fill:#4fc3f7,stroke:#333,color:#000
    style membrane_penetration fill:#4fc3f7,stroke:#333,color:#000
    style tau_protein fill:#4fc3f7,stroke:#333,color:#000
    style phosphatidylserine_1 fill:#4fc3f7,stroke:#333,color:#000
    style tau_protein_2 fill:#4fc3f7,stroke:#333,color:#000
    style membrane_curvature fill:#4fc3f7,stroke:#333,color:#000
    style tau_aggregation fill:#4fc3f7,stroke:#333,color:#000
    style pH_acidification fill:#4fc3f7,stroke:#333,color:#000
    style tau_aggregation_3 fill:#4fc3f7,stroke:#333,color:#000
    style cholesterol_depletion fill:#4fc3f7,stroke:#333,color:#000
    style tau_conformational_change fill:#4fc3f7,stroke:#333,color:#000
    style membrane_disruption fill:#4fc3f7,stroke:#333,color:#000
    style tau_aggregation_4 fill:#4fc3f7,stroke:#333,color:#000
    style ATP_depletion fill:#4fc3f7,stroke:#333,color:#000
    style tau_aggregation_5 fill:#4fc3f7,stroke:#333,color:#000
    style membrane_asymmetry fill:#4fc3f7,stroke:#333,color:#000

⚖️ Evidence

⚖️ Evidence Matrix5 supports0 contradicts
Supports
MAPT mutations, tauopathy, and mechanisms of neurodegeneration.
Lab Invest2019PMID:30742061medium
Supports
Tau-targeting antisense oligonucleotide MAPT(Rx) in mild Alzheimer's disease: a phase 1b, randomized, placebo-controlled trial.
Nat Med2023PMID:37095250medium
Supports
Interactions between Microtubule-Associated Protein Tau (MAPT) and Small Molecules.
Cold Spring Harb Perspect Med2017PMID:27940599medium
Supports
ELAVL4, splicing, and glutamatergic dysfunction precede neuron loss in MAPT mutation cerebral organoids.
Cell2021PMID:34314701medium
Supports
The six brain-specific TAU isoforms and their role in Alzheimer's disease and related neurodegenerative dementia syndromes.
Alzheimers Dement2024PMID:38556838medium
📖 Linked Papers

No linked papers recorded for this hypothesis yet.

🏥 Translation

🧬 3D Protein Structure — MAPT

🧬 PDB 5O3L Click to expand

Experimental structure from RCSB PDB | Powered by Mol*

💉 Clinical Trials

No clinical trials data linked to this hypothesis yet.

No curated ClinVar variants loaded for this hypothesis.

Run scripts/backfill_clinvar_variants.py to fetch P/LP/VUS variants.

🔍 Search ClinVar for MAPT →

No DepMap CRISPR Chronos data found for MAPT.

Run python3 scripts/backfill_hypothesis_depmap.py to populate.

🏆 Tournament

🏆 Arenas / Elo

No arena matches recorded yet. Browse Arenas →

📊 Market Indicators

7d Trend
Stable
7d Momentum
▲ 0.0%
Volatility
High
0.0535
Events (7d)
0
Price History
▲6.0%

💾 Resource Usage

LLM Tokens
12,936
$0.0776
Total Cost
$0.0776

🔮 Predictions

🔎 Predictions vs Observations2 predictions · 0 with recorded observations
PredictionPredictedObservedStatusConf
IF SH-SY5Y neuroblastoma cells engineered to overexpress mutant MAPT (P301L) are treated with size-selective anti-tau nanobodies for 4-6 hours, THEN the nanobodies will accumulate significantly higherEnlarged tau-vesicles will show >60% higher nanobody fluorescence intensity compared to normal-sized vesicles, with colocalization coefficient >0.75— no observation —pending0.55
IF primary cortical neurons from PS19 tauopathy mice (expressing P301L MAPT) are treated with size-selective anti-MAPT nanobodies versus non-selective nanobodies for 24 hours, THEN size-selective nanoSize-selective nanobodies will achieve ≥2.5-fold higher enrichment in enlarged tau endosomes (≥600nm) compared to non-selective nanobodies, with <30% increase i— no observation —pending0.50
🔮 Falsifiable Predictions (2)
pendingconf 55%
IF SH-SY5Y neuroblastoma cells engineered to overexpress mutant MAPT (P301L) are treated with size-selective anti-tau nanobodies for 4-6 hours, THEN the nanobodies will accumulate significantly higher in enlarged tau-positive vesicles (>500nm diameter) compared to normal-sized vesicles (<300nm) with
Predicted outcome: Enlarged tau-vesicles will show >60% higher nanobody fluorescence intensity compared to normal-sized vesicles, with colocalization coefficient >0.75
Falsification: No significant difference in nanobody fluorescence between enlarged and normal-sized vesicles (difference <20%), or preferential accumulation in normal-sized vesicles
pendingconf 50%
IF primary cortical neurons from PS19 tauopathy mice (expressing P301L MAPT) are treated with size-selective anti-MAPT nanobodies versus non-selective nanobodies for 24 hours, THEN size-selective nanobodies will show preferential targeting to enlarged tau-containing endosomes while maintaining reduc
Predicted outcome: Size-selective nanobodies will achieve ≥2.5-fold higher enrichment in enlarged tau endosomes (≥600nm) compared to non-selective nanobodies, with <30%
Falsification: Size-selective nanobodies show no greater than 1.5-fold enrichment in enlarged tau endosomes compared to non-selective nanobodies, or demonstrate >50% increased penetration into normal-sized endosomes
View on SciDEX ↗